Peter is a seasoned executive in the molecular diagnostics arena with a wealth of experience in strategic leadership, business development and commercialisation. Peter has joined Premaitha Health from a prestigious role as Vice President, Head of Diagnostics at GSK. Peter led GSK’s Diagnostic Nucleus focused on supporting the diagnostic needs of GSK’s Clinical Development Programs across all business units.
Peter was formerly Vice President of Pharma Business Development for QIAGEN driving the uptake of companion diagnostic programs in multiple partnerships across the pharma industry. Before this he was VP Business Development at DxS prior to its acquisition by QIAGEN in September 2009. Peter’s role at DxS was pivotal in securing a number of the company’s companion diagnostic agreements for KRAS and EGFR with key pharma clients. Peter was also VP of Marketing and Sales for Vysis Europe (now Abbott Molecular Diagnostics), where he lead the introduction PathVysion Her2 for selection of patients eligible for Herceptin in the EU.
Peter has a strong entrepreneurial background and has held senior executive roles, including CEO, at a number of early stage diagnostics and life science companies including Quantase (Bio-Rad) where Peter worked in the field of prenatal screening. Further executive roles have been held at Gentronix, Biogenex and Pronostics. He began his commercial diagnostic career with Syva (Dade Behring/Bayer/Siemens) and BD’s Immunocytometry division. Peter is a founder and held a Board position for two years at EPEMED, a not for profit European organisation to bring together global forces in personalised medicine.